ClinicalTrials.gg
CompletedNCT05602025Updated Jun 16, 2026Results posted

A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants

A Phase 1 interventional study of Depemokimab in Asthma, sponsored by GlaxoSmithKline. Completed at 3 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing depemokimab in Asthma — 3 open to participants now, 3 under way, 3 of them phase 3. depemokimab · Asthma.

Enrollment
7th of 10
140 · median 273
Started
2022
with 1 other
Phase 1
3 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
10 of 10
GlaxoSmithKline

Among the 10 studies testing depemokimab in Asthma, this one is the 7th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 7th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 10 studies testing depemokimab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About depemokimab

depemokimab: first FDA approval 2025 (EXDENSUR), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing depemokimab in Asthma, or all of them as a file.
02

Study summary

This study will compare the pharmacokinetics, safety, tolerability, and immunogenicity of Depemokimab administered via a SSD or autoinjector in healthy participants.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Autoinjector
  • Depemokimab
  • Healthy Participants
  • Safety Syringe Device
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, clinical laboratory tests, vital sign measurements, and 12-lead results.
  • Body weight greater than or equal to (>=) 50 kilograms (kg) (110 pounds-mass/Ibs) and within the range 19 to 30 kg per meter square (inclusive).
  • Women who have the potential to become pregnant must use a form of highly-effective .
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • History or presence of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, constituting a risk when taking the study intervention, or interfering with the interpretation of data.
  • Participants with allergy/intolerance to a monoclonal antibody or biologic or participants with a previous history of multiple or severe drug allergies/intolerance.
  • Current evidence or recent history of an infective illness.
  • A positive pre-study drug/alcohol screen or a history (or suspected history) of alcohol misuse or substance abuse
  • Clinically significant abnormalities.
  • Positive test for severe acute respiratory syndrome coronavirus (SARS-CoV-2) at screening.
  • Recent prior or concurrent clinical study experience.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Depemokimab via SSD

    Participants received a single subcutaneous dose of 100 milligrams (mg) of depemokimab administered via a Safety Syringe Device (SSD) on Day 1.

    Biological: Depemokimab

  • Experimental
    Depemokimab via autoinjector

    Participants received a single subcutaneous dose of 100 mg of depemokimab administered via an autoinjector on Day 1.

    Biological: Depemokimab

Interventions

  • BiologicalDepemokimab

    Depemokimab was administered via SSD or autoinjector.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Depemokimab

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  2. Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

Secondary outcomes

  1. Area Under the Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration (AUC[0-t]) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  2. Time to Maximum Observed Plasma Concentration (Tmax) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  3. Apparent Clearance Following Extravascular Administration (CL/F) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  4. Apparent Volume of Distribution Following Extravascular Administration (Vd/F) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  5. Terminal Elimination Rate Constant (Lambda z) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  6. Terminal Elimination Half-Life (T1/2) Following Administration of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  7. Time of Last Measurable Plasma Concentrations (Tlast) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  8. Percentage of AUC (0-Inf) Due to Extrapolation From the Time of the Last Observed Concentration (Tlast) to Infinity (%AUCex) of Depemokimab

    Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods. The percentage of AUC (0-inf) obtained by extrapolation (%AUCex) was calculated as: (AUC\[0-inf\] - AUC\[0-t\]) /AUC(0-inf)\*100.

    Time frame: Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose

  9. Number of Participants With Presence of Positive Anti-depemokimab Antibodies

    Blood samples were collected and analyzed for the presence of anti- depemokimab antibodies using a validated immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1), Weeks 4, 8, 12 and 26

  10. Number of Participants With Positive Neutralizing Antibodies to Depemokimab

    Blood samples were collected for determination of positive neutralizing antibodies. A neutralizing antibody assay was performed. Neutralizing antibody test was only carried out for participants who have had a positive confirmatory binding antibody test result at visit. A participant was considered positive if they had at least one positive post-Baseline neutralizing antibody result. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

    Time frame: Baseline (Day 1), Weeks 4, 8, 12 and 26

07

Results

Posted Jun 16, 2026

Participant flow

This was a single-dose study in healthy adult participants to compare the pharmacokinetics of depemokimab when delivered with a Safety Syringe Device (SSD) or an Autoinjector.

Participant flow — Overall Study
MilestoneDepemokimab Via SSDDepemokimab Via Autoinjector
Started7070
Completed6969
Not completed11
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) of Depemokimab

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Observed Plasma Concentration (Cmax) of Depemokimab
Micrograms per milliliterDepemokimab Via SSDDepemokimab Via Autoinjector
Maximum Observed Plasma Concentration (Cmax) of Depemokimab14.68 ± 24.1714.97 ± 23.29
PrimaryArea Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Day*microgram/mL
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Depemokimab
Day*microgram/mLDepemokimab Via SSDDepemokimab Via Autoinjector
Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0-inf]) of Depemokimab1061.05 ± 26.891078.66 ± 28.39
SecondaryArea Under the Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration (AUC[0-t]) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Day*microgram/mL
Area Under the Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration (AUC[0-t]) of Depemokimab
Day*microgram/mLDepemokimab Via SSDDepemokimab Via Autoinjector
Area Under the Concentration-time Curve From Time Zero to Time of Last Observed Quantifiable Concentration (AUC[0-t]) of Depemokimab999.38 ± 26.071014.29 ± 27.35
SecondaryTime to Maximum Observed Plasma Concentration (Tmax) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Median · Day
Time to Maximum Observed Plasma Concentration (Tmax) of Depemokimab
DayDepemokimab Via SSDDepemokimab Via Autoinjector
Time to Maximum Observed Plasma Concentration (Tmax) of Depemokimab12.97 (4.0 to 28.9)12.43 (3.9 to 28.0)
SecondaryApparent Clearance Following Extravascular Administration (CL/F) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Liters/day
Apparent Clearance Following Extravascular Administration (CL/F) of Depemokimab
Liters/dayDepemokimab Via SSDDepemokimab Via Autoinjector
Apparent Clearance Following Extravascular Administration (CL/F) of Depemokimab0.09 ± 26.890.09 ± 28.39
SecondaryApparent Volume of Distribution Following Extravascular Administration (Vd/F) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution Following Extravascular Administration (Vd/F) of Depemokimab
LitersDepemokimab Via SSDDepemokimab Via Autoinjector
Apparent Volume of Distribution Following Extravascular Administration (Vd/F) of Depemokimab5.64 ± 25.025.51 ± 27.23
SecondaryTerminal Elimination Rate Constant (Lambda z) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Per day
Terminal Elimination Rate Constant (Lambda z) of Depemokimab
Per dayDepemokimab Via SSDDepemokimab Via Autoinjector
Terminal Elimination Rate Constant (Lambda z) of Depemokimab0.02 ± 24.460.02 ± 23.49
SecondaryTerminal Elimination Half-Life (T1/2) Following Administration of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Day
Terminal Elimination Half-Life (T1/2) Following Administration of Depemokimab
DayDepemokimab Via SSDDepemokimab Via Autoinjector
Terminal Elimination Half-Life (T1/2) Following Administration of Depemokimab41.45 ± 24.4641.19 ± 23.49
SecondaryTime of Last Measurable Plasma Concentrations (Tlast) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Mean · Day
Time of Last Measurable Plasma Concentrations (Tlast) of Depemokimab
DayDepemokimab Via SSDDepemokimab Via Autoinjector
Time of Last Measurable Plasma Concentrations (Tlast) of Depemokimab179.21 ± 13.510177.74 ± 16.385
SecondaryPercentage of AUC (0-Inf) Due to Extrapolation From the Time of the Last Observed Concentration (Tlast) to Infinity (%AUCex) of Depemokimab

Blood samples were collected at indicated time points for PK analysis of depemokimab. PK analysis was conducted using standard non-compartmental methods. The percentage of AUC (0-inf) obtained by extrapolation (%AUCex) was calculated as: (AUC\[0-inf\] - AUC\[0-t\]) /AUC(0-inf)\*100.

Time frame:
Day 1: Pre-dose and 2, 8 hours post-dose; Days 2, 3, 5, 8, 15, 29, 57, 85, 127, 169 and 183 post-dose
Reported as:
Geometric mean · Percentage of AUC extrapolation
Percentage of AUC (0-Inf) Due to Extrapolation From the Time of the Last Observed Concentration (Tlast) to Infinity (%AUCex) of Depemokimab
Percentage of AUC extrapolationDepemokimab Via SSDDepemokimab Via Autoinjector
Percentage of AUC (0-Inf) Due to Extrapolation From the Time of the Last Observed Concentration (Tlast) to Infinity (%AUCex) of Depemokimab5.02 ± 73.245.06 ± 64.04
SecondaryNumber of Participants With Presence of Positive Anti-depemokimab Antibodies

Blood samples were collected and analyzed for the presence of anti- depemokimab antibodies using a validated immunoassay. The assay involved screening, confirmation and titration steps. If serum samples tested positive in the screening assay, they were considered 'potentially positive' and were further analyzed for the specificity using the confirmation assay. Samples that confirmed positive in the confirmation assay were reported as 'positive'. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1), Weeks 4, 8, 12 and 26
Reported as:
Count of participants · Participants
Number of Participants With Presence of Positive Anti-depemokimab Antibodies
ParticipantsDepemokimab Via SSDDepemokimab Via Autoinjector
Baseline (Day 1)10
Week 410
Week 810
Week 1210
Week 2621
SecondaryNumber of Participants With Positive Neutralizing Antibodies to Depemokimab

Blood samples were collected for determination of positive neutralizing antibodies. A neutralizing antibody assay was performed. Neutralizing antibody test was only carried out for participants who have had a positive confirmatory binding antibody test result at visit. A participant was considered positive if they had at least one positive post-Baseline neutralizing antibody result. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.

Time frame:
Baseline (Day 1), Weeks 4, 8, 12 and 26
Reported as:
Count of participants · Participants
Number of Participants With Positive Neutralizing Antibodies to Depemokimab
ParticipantsDepemokimab Via SSDDepemokimab Via Autoinjector
Baseline (Day 1)1—
Week 41—
Week 81—
Week 121—
Week 2611

Adverse events

Collected over All-cause mortality, serious adverse events (SAEs) and common greater than equal to (>=) 3 percent (%) non-serious adverse events (Non-SAEs) were collected up to 211 days. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Depemokimab Via SSD0/70 (0%)0/70 (0%)16/70 (22.9%)
Depemokimab Via Autoinjector0/70 (0%)2/70 (2.9%)24/70 (34.3%)
Most frequent serious events
Most frequent serious events
EventDepemokimab Via SSDDepemokimab Via Autoinjector
Pelvic inflammatory diseaseInfections and infestations0/701/70
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/701/70
Most frequent other events
Showing 10 of 11
Most frequent other events
EventDepemokimab Via SSDDepemokimab Via Autoinjector
HeadacheNervous system disorders7/706/70
Injection site swellingGeneral disorders1/704/70
Abdominal painGastrointestinal disorders1/703/70
DiarrhoeaGastrointestinal disorders1/703/70
NauseaGastrointestinal disorders3/701/70
VomitingGastrointestinal disorders3/701/70
Injection site bruisingGeneral disorders3/701/70
Injection site erythemaGeneral disorders2/703/70
COVID-19Infections and infestations2/703/70
Viral upper respiratory tract infectionInfections and infestations0/703/70

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)Depemokimab Via SSDDepemokimab Via AutoinjectorTotal
Mean36.2 ± 7.7634.8 ± 8.2535.5 ± 8.01
Sex: Female, Male
Sex: Female, Male(Participants)Depemokimab Via SSDDepemokimab Via AutoinjectorTotal
Female354075
Male353065
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Depemokimab Via SSDDepemokimab Via AutoinjectorTotal
American Indian or Alaska Native101
Asian347
Black or African American152237
White454388
Mixed Race617
08

Study locations

3 sites
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
  • GSK Investigational Site
    Austin, Texas 78744, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2023, 10 months.

Results were first posted in Jun 2026, 2 years 7 months after primary completion.

Of 173 industry-sponsored phase 1 interventional studies under Asthma, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 10 months is above that.

Counting every sponsor, half of 200 studies reached it within 6 months; a quarter within 3 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2022
First posted
Nov 1, 2022
StartActual
Dec 13, 2022
Primary completionActual
Oct 23, 2023
CompletionActual
Oct 23, 2023
Results first posted
Jun 16, 2026
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05602025
Lead sponsor
GlaxoSmithKline
Collaborators
PPD Development, LP
Responsible party
Sponsor
First posted
Nov 1, 2022
Start date
Dec 13, 2022
Primary completion
Oct 23, 2023
Completion
Oct 23, 2023
Results posted
Jun 16, 2026
Last update
Jun 16, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Depemokimab

Start the discussion